Richard Weller (MD, FRCP(Ed))

Personal Chair of Medical Dermatology

  • Centre for Inflammation Research

Contact details

Background

I graduated in medicine at St Thomas’ Hospital, University of London (now part of King’s College, London) and undertook my general/internal medicine training in the north of England and in Australia. Having gained my MRCP I trained in dermatology at the Institute of Dermatology (St John’s) in London, and in Aberdeen and Edinburgh. I spent some time out of my clinical training to complete a research MD degree.  Having completed my dermatology training, I gained a scholarship from the University of Edinburgh, and spent three years in post-doctoral research training in the laboratories of Prof Victoria Kolb-Bachofen, Heinrich-Heine Universität, Dusseldorf, and of Dr Tim Billiar, University of Pittsburgh, USA.I was recruited from America to the post of Senior Lecturer (latterly Professor) in Dermatology in Edinburgh and am a Principal Investigator at the Centre for Inflammation Research. My time is divided between clinical duties, where I am an honorary NHS Consultant Dermatologist with a particular interest in medical dermatology and eczema, and the University where I have an active research group, with a focus on the effects of sunlight on general health. 

CV

PDF icon 154813.pdf

Qualifications

MB BS, MD, FRCP(Ed)

Responsibilities & affiliations

Principle Investigator, Centre for Inflammation Research.  Honorary Consultant Dermatologist NHS Lothian

Open to PhD supervision enquiries?

Yes

Research summary

Ultraviolet radiation and the skin

In 1996 I made the first description of nitric oxide (NO) production on the skin surface. NO at the time was known to dilate blood vessels and thus help regulate blood pressure - work for which the discoverers received the Nobel Prize for Medicine or Physiology in 1998 - but it was also involved in control of a number of other functions. Initially working in Aberdeen and Edinburgh and then at Heinrich-Heine University, Dusseldorf and the University of Pittsburgh I set out to uncover the role of this naturally produced NO in the skin.  Following the standard dermatological dogma of the time I spent my time in Germany and America looking at the effects of NO on keratinocyte (skin cell) survival after sun exposure. Although I was able to show effects of NOS derived NO in inhibiting apoptosis in cell culture and murine models, I was unable to replicate this in man. Developing my work in Edinburgh on healthy volunteers, I was able to show that human skin contains large stores of nitrogen oxides (NOx) and that these are photo-reduced by UV radiation releasing NO to the circulation, with systemic effects, in particular lowering of BP. This work is summarised in a TED talk.

Work from my group and with a number of international collaborators is now finding a growing number of physiological and homeostatic processes that are dependent on this UV-skin NO mobilisation pathway. Partly spurred on by the discovery of this mechanism, the risk-benefit ratio for population sunlight exposure is being reconsidered in Europe, Australia and the USA. It is becoming clear that Vitamin D synthesis is not the only sun-dependent homeostatic mechanism, and may in fact only account for a small part of health  benefits attributed to sun exposure. We have recently shown that UVA independently of vitamin D correlates inversely with deaths from COVID, which has important public health implications.  Using the UK Biobank we have now shown that for a UK population, increased sunlight exposure correlates with reduced all-cause, cardiovascular and cancer mortality. 

Current research interests

We are now studying the mechanisms by which sunlight may reduce cancer mortality. Our studies involve irradiation of human volunteers with solar simulator lamps over winter with measurements taken pre and post solar simulation using a variety of techniques. We are able to cross reference the data we derive from our interventional research studies with the growing body of observational data from large studies such as the UK Biobank to add power and clinical significance to our research.